Strategic funding Stem Pharm recently secured a 2.5M Phase II SBIR grant from NIH/NIA, signaling validated research capabilities and potential for government-funded collaborations or co-development opportunities with biopharma partners.

Neurodegenerative focus Core programs target epilepsy, neurodegeneration, and brain cancer using human 3D neuro-immune organoids, creating collaboration and licensing avenues with companies aiming to validate targets in PD, Alzheimer's, ALS, and related disorders.

Collaborative model Active partnerships with Verge Genomics to develop disease models for Parkinson’s disease demonstrate openness to AI-driven target discovery and external validation, suggesting opportunities for strategic alliances and joint ventures.

Small team agility With a lean headcount (2–10 employees) and a local Madison, WI base, there is potential to scale business development through targeted partnerships, contract research, and milestone-driven collaborations rather than full integration.

Clinical alignment Leveraging human organoid platforms that model neuroinflammation positions Stem Pharm to offer target validation services and translational data packages to pharma companies pursuing neurology assets with clear path to clinical development.